Traws Pharma (TRAW) Competitors $1.58 -0.05 (-3.07%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$1.60 +0.01 (+0.95%) As of 07/25/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRAW vs. KALA, MAAQ, KPTI, ITRM, HYPD, BDRX, SNYR, KZR, ESLA, and CLNNShould you be buying Traws Pharma stock or one of its competitors? The main competitors of Traws Pharma include KALA BIO (KALA), Mana Capital Acquisition (MAAQ), Karyopharm Therapeutics (KPTI), Iterum Therapeutics (ITRM), Hyperion DeFi (HYPD), Biodexa Pharmaceuticals (BDRX), Synergy CHC (SNYR), Kezar Life Sciences (KZR), Estrella Immunopharma (ESLA), and Clene (CLNN). These companies are all part of the "pharmaceutical products" industry. Traws Pharma vs. Its Competitors KALA BIO Mana Capital Acquisition Karyopharm Therapeutics Iterum Therapeutics Hyperion DeFi Biodexa Pharmaceuticals Synergy CHC Kezar Life Sciences Estrella Immunopharma Clene Traws Pharma (NASDAQ:TRAW) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk. Which has better earnings and valuation, TRAW or KALA? KALA BIO has higher revenue and earnings than Traws Pharma. KALA BIO is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTraws Pharma$230K38.19-$166.52M-$32.81-0.05KALA BIO$3.89M13.41-$38.51M-$8.24-0.98 Does the media favor TRAW or KALA? In the previous week, KALA BIO had 1 more articles in the media than Traws Pharma. MarketBeat recorded 2 mentions for KALA BIO and 1 mentions for Traws Pharma. Traws Pharma's average media sentiment score of 1.89 beat KALA BIO's score of 0.17 indicating that Traws Pharma is being referred to more favorably in the media. Company Overall Sentiment Traws Pharma Very Positive KALA BIO Neutral Do insiders and institutionals believe in TRAW or KALA? 8.0% of Traws Pharma shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 13.6% of Traws Pharma shares are held by insiders. Comparatively, 8.3% of KALA BIO shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, TRAW or KALA? Traws Pharma has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, KALA BIO has a beta of -1.88, indicating that its share price is 288% less volatile than the S&P 500. Do analysts recommend TRAW or KALA? KALA BIO has a consensus price target of $13.00, indicating a potential upside of 60.69%. Given KALA BIO's stronger consensus rating and higher possible upside, analysts plainly believe KALA BIO is more favorable than Traws Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Traws Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00KALA BIO 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is TRAW or KALA more profitable? KALA BIO has a net margin of 0.00% compared to Traws Pharma's net margin of -15,245.81%. Traws Pharma's return on equity of 0.00% beat KALA BIO's return on equity.Company Net Margins Return on Equity Return on Assets Traws Pharma-15,245.81% N/A -193.21% KALA BIO N/A -369.29%-64.99% SummaryKALA BIO beats Traws Pharma on 10 of the 16 factors compared between the two stocks. Get Traws Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TRAW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRAW vs. The Competition Export to ExcelMetricTraws PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.07M$2.49B$5.69B$9.50BDividend YieldN/A1.65%4.58%4.01%P/E Ratio-0.059.0528.1020.05Price / Sales38.19612.51432.4490.07Price / CashN/A165.2136.2258.56Price / Book-0.185.168.665.87Net Income-$166.52M$30.99M$3.25B$258.55M7 Day Performance-1.25%7.74%4.23%3.74%1 Month Performance10.49%16.27%10.52%11.75%1 Year PerformanceN/A-1.88%34.41%18.03% Traws Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRAWTraws Pharma0.9471 of 5 stars$1.58-3.1%N/AN/A$9.07M$230K-0.0517Positive NewsKALAKALA BIO3.9102 of 5 stars$5.50-3.5%$13.00+136.4%+11.7%$35.49MN/A-0.6730MAAQMana Capital AcquisitionN/A$4.30-6.9%N/A+847.8%$34.94MN/A0.001Gap UpKPTIKaryopharm Therapeutics3.8333 of 5 stars$3.89-3.2%$37.40+861.4%-69.8%$33.61M$145.24M-0.29380ITRMIterum Therapeutics2.0519 of 5 stars$0.83-4.7%$9.00+984.3%-35.8%$33.20MN/A-0.8410Positive NewsHYPDHyperion DeFi1.1236 of 5 stars$11.52-1.0%$2.00-82.6%-93.3%$33.18M$60K-0.2040Positive NewsAnalyst DowngradeGap UpBDRXBiodexa Pharmaceuticals0.2928 of 5 stars$0.90+6.0%N/AN/A$32.93M$470K0.0020Positive NewsSNYRSynergy CHC4.0745 of 5 stars$3.56+1.7%$10.00+180.9%N/A$32.73M$33.59M0.0040Gap DownKZRKezar Life Sciences4.1212 of 5 stars$4.45+3.5%$39.50+787.6%-34.5%$32.51MN/A-0.4160ESLAEstrella Immunopharma3.2141 of 5 stars$0.87+4.0%$16.00+1,730.7%-47.9%$31.61MN/A-3.36N/ANews CoverageGap DownCLNNClene3.4621 of 5 stars$3.81-1.6%$40.00+949.9%-18.2%$31.51M$340K-0.94100 Related Companies and Tools Related Companies KALA BIO Competitors Mana Capital Acquisition Competitors Karyopharm Therapeutics Competitors Iterum Therapeutics Competitors Hyperion DeFi Competitors Biodexa Pharmaceuticals Competitors Synergy CHC Competitors Kezar Life Sciences Competitors Estrella Immunopharma Competitors Clene Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRAW) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Traws Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Traws Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
